Galantamine

CLINICAL USE

Mild to moderate dementia in Alzheimer’s disease

DOSE IN NORMAL RENAL FUNCTION

4–12 mg twice daily

PHARMACOKINETICS

  • Molecular weight                           :368.3 (as hydrobromide)
  • %Protein binding                           :18
  • %Excreted unchanged in urine     : 18–22
  • Volume of distribution (L/kg)       :175 litres
  • half-life – normal/ESRD (hrs)      :7–8 (XL: 8–10)/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function but start with lower doses

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Dialysed. Dose as in GFR
  • <10           : mL/min
  • HD                     :Dialysed. Dose as in GFR
  • <10           : mL/min
  • HDF/high flux   :Dialysed. Dose as in GFR
  • <10           : mL/min
  • CAV/VVHD      :Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • Antibacterials: erythromycin increases plasma concentration of galantamine

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia